Bifogade filer
PDF
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Läkemedel & Handel |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
ODI Pharma AB ("ODI" or the "Company") hereby publishes its interim report for the period July 2025 - March 2026. The report is available as an attached document to this press release and on the Company's website (www.odipharma.com). Below is a summary of the report.
"ODI Pharma continues to deliver significant and consistent commercial growth, supported by a more stable market environment and improved operating conditions. Over the past three quarters, the Company has achieved record sales levels, and year-to-date sales already exceed any previous full fiscal year in ODI Pharma's history. This development reflects the progress made across the business and confirms the strength of the commercial foundation that has been built in recent periods." - Volker Wiederrich, Chairman of the Board, ODI Pharma.
Third quarter (2026-01-01 - 2026-03-31)
- The Group's net sales amounted to SEK 12,712,029 (2,934,337).
- The Group's profit after financial items amounted to SEK 126,614 (-340,612).
- Result per share amounted to SEK 0.01 (-0.02).*
Nine months (2025-07-01 - 2026-03-31)
- The Group's net sales amounted to SEK 29,753,825 (3,064,896).
- The Group's profit after financial items amounted to SEK 1,417,177 (-4,153,493).
- Result per share amounted to SEK 0.08 (-0.26).*
- The solidity as of 2026-03-31 was 17% (11%).**
* The Company's result per share: The result for the period divided by the number of shares at the end of the period. The total number of shares as of 31st of March 2026, amounted to 18,348,419 (15,915,034) shares. The result per share based on the average number of shares of 18,348,419 (15,915,034) amounts to SEK 0.08 (-0.26) for the first nine months 2025-07-01 to 2026-03-31.
** Solidity: Equity divided by total capital.
Highlights during the third quarter
- No significant events occurred after the end of the period.
Highlights after the end of the period
- No significant events occurred after the end of the period.
For more information on ODI Pharma, please contact:
Volker Wiederrich, Chairman, ODI Pharma AB
E-mail: info@odipharma.com
ODI Pharma AB
ODI Pharma, based on its European network, subsidiaries and affiliates, is a producer and representative of finished pharmaceutical cannabis products with a focus on distribution to the medical cannabis market in Europe through its subsidiary ODI Pharma Polska Sp. z o.o. ODI Pharma intends to provide a high-quality product at a competitive price compared to competitors in Poland, thereby becoming the number one provider of medical cannabis in Poland. ODI Pharma also strives to be on the forefront of understanding the medical applications of the product as well as introducing new, innovative products to the European patients in need. The Company will continue to team up with the most knowledgeable and best renown partners in the industry to achieve its goals.